Get the Stockscreener App
0.551
0.18%
0.001
Pharmacyte Biotech Inc stock is traded at $0.551, with a volume of 131.48K.
It is up +0.18% in the last 24 hours and down -20.05% over the past month.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
See More
Previous Close:
$0.55
Open:
$0.56
24h Volume:
131.48K
Relative Volume:
0.74
Market Cap:
$5.92M
Revenue:
-
Net Income/Loss:
$-3.28M
P/E Ratio:
-0.5295
EPS:
-1.0406
Net Cash Flow:
$-4.80M
1W Performance:
-6.63%
1M Performance:
-20.05%
6M Performance:
-19.04%
1Y Performance:
-38.01%
1-Day Range:
$0.54
$0.5712
1-Week Range:
$0.53
$0.60
52-Week Range:
$0.53
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Name
Pharmacyte Biotech Inc
Sector
Industry
Phone
(917) 595.2850
Address
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.86 | 2.83B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.89 | 388.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.88 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.45 | 348.74M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
48.03 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Stock (PMCB) Latest News
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - tradingkey.com
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60New Highs New Lows - dars.gov.et
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
- po-news-eg.net
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
PMCB Q1 2026 Earnings: Losses Narrow as Biotech Advances Pipeline Amid Positive Market SentimentROA Comparison - Bölüm Sonu Canavarı
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Loss Per Share of $0.09 as Clinical Pipeline AdvancesEarnings Quality Score - po-news-eg.net
PharmaCyte Biotech | DEF 14A: Definitive information statements - Moomoo
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Risk Report - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMCB Q1 2026 Earnings: Reported Loss of -$0.09 Per Share as Stock DeclinesAnalyst Consensus Shift - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss, Shares Slide 8%Strong Earnings Momentum - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Q1 2026 Earnings: Modest Loss Reported Amid Early-Stage DevelopmentEarnings Surprise Report - dars.gov.et
PMCB Technical Analysis & Stock Price Forecast - Intellectia AI
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre‑Revenue Biotech Reports Loss, Shares Slide 3.5%Earnings Surprise Stocks - newsline.com
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. - marketscreener.com
PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector FocusChaikin Flow - newsline.com
PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79Fundamental Weighted - dars.gov.et
PharmaCyte Biotech (PMCB) Jumps 12.76% as Biotech Speculation Heats UpBuyback Factor - The Legal Advocate
Pharmacyte Biotech Inc Stock (PMCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):